[Ultratard HM, a new human insulin. Advantages as compared to current preparations?]

Abstract

Ultratard HM, a new human insulin, was studied in 10 patients with type II diabetes mellitus not previously treated with insulin. A control group consisted of 12 patients on Protaphane HM and 22 patients on Monotard MC. All patients tolerated the treatment well. After 6 months of therapy antiinsulin antibodies were detectable in only one patient on Ultratard HM. Therefore, in adult diabetics it is difficult to demonstrate a difference of antigenicity between human and porcine insulin. In another study blood glucose profiles were compared in 7 stable diabetics on Ultratard HM and Monotard HM. In our patients there was no significant difference in the activity profile of these 2 insulins.